Eurofins Scientific Shares Rebound to €60.58 After Holding Key Support
Eurofins Scientific regains momentum during the session, reaching €60.58, in a Paris market trending sharply upwards. The CAC 40 is up 2.95% at midday, amid easing geopolitical tensions in the Middle East. The bioanalytical testing specialist's stock is attempting to stabilize its trajectory after a disappointing quarterly report in April.
Eurofins Scientific's stock advances 3.13% to €60.58, after slipping below €58 on Monday. However, the stock remains distant from its 50-day and 200-day moving averages, both around €64, maintaining a medium-term downward trend. The RSI at 36 indicates seller fatigue over the past weeks, without yet entering a characterized oversold zone. The price is moving in the lower part of the Bollinger Bands, close to the lower boundary at €55.54. The support identified at €57.54 held during the last two sessions, paving the way for the observed rebound during the day. Over three months, the decline reaches 11.51%.
Busy Schedule Following a Disappointing Quarterly Publication
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's movement occurs without any identified catalyst in the group's news. To recall, the first quarter publication on April 22 caused the stock to drop more than 10% in one session, with organic growth limited to 2.5%, hindered by weather conditions in Europe and North America. The group then maintained its organic growth targets for the fiscal year 2026. Several strategic operations mark the semester. The divestiture of the MET Labs division to UL Solutions, valued at €575 million, is part of the focus on life testing. Concurrently, a seventh share buyback program, covering 4.5% of the capital, was launched at the end of April. Upcoming key dates in the financial calendar include the general assembly on May 27, followed by the semi-annual results on September 18.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.